Avalo Therapeutics (AVTX)

• Market cap: $83.9M
• 1 day: 11.13%
• 5 days: 15.13%
• 1 month: 4.31%
• 3 months: -14.91%
• 6 months: -2.56%
• Year to date: -5.22%
• 1 year: 42.17%
• 5 years: -99.88%
• 10 years: -99.93%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Employees: 19

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

14% more funds holding

Funds holding: 29 [Q3] → 33 (+4) [Q4]

3.37% more ownership

Funds ownership: 68.63% [Q3] → 71.99% (+3.37%) [Q4]

11% less capital invested

Capital invested by funds: $63.2M [Q3] → $56M (-$7.25M) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $24 200% upside
• Avg. target: $37 367% upside
• High target: $48 501% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler Yasmeen Rahimi 48% 1-year accuracy 13 / 27 met price target	501% upside $48	Overweight Initiated	28 Feb 2025
BTIG Julian Harrison 18% 1-year accuracy 3 / 17 met price target	401% upside $40	Buy Initiated	19 Dec 2024
LUCID CAPITAL MARKETS Dev Prasad 33% 1-year accuracy 1 / 3 met price target	200% upside $24	Buy Initiated	17 Dec 2024